ATE529126T1 - Stabilisierte pharmazeutische peptid zusammensetzungen - Google Patents

Stabilisierte pharmazeutische peptid zusammensetzungen

Info

Publication number
ATE529126T1
ATE529126T1 AT04735873T AT04735873T ATE529126T1 AT E529126 T1 ATE529126 T1 AT E529126T1 AT 04735873 T AT04735873 T AT 04735873T AT 04735873 T AT04735873 T AT 04735873T AT E529126 T1 ATE529126 T1 AT E529126T1
Authority
AT
Austria
Prior art keywords
peptide compositions
stabilized pharmaceutical
pharmaceutical peptide
stabilized
peptide
Prior art date
Application number
AT04735873T
Other languages
English (en)
Inventor
Claus Juul-Mortensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/DK2004/000381 external-priority patent/WO2004105790A1/en
Application granted granted Critical
Publication of ATE529126T1 publication Critical patent/ATE529126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04735873T 2003-06-03 2004-06-03 Stabilisierte pharmazeutische peptid zusammensetzungen ATE529126T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300820 2003-06-03
US47628203P 2003-06-05 2003-06-05
DKPA200400063 2004-01-19
US53848704P 2004-01-22 2004-01-22
PCT/DK2004/000381 WO2004105790A1 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number Publication Date
ATE529126T1 true ATE529126T1 (de) 2011-11-15

Family

ID=36816397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735873T ATE529126T1 (de) 2003-06-03 2004-06-03 Stabilisierte pharmazeutische peptid zusammensetzungen

Country Status (5)

Country Link
US (1) US20060183682A1 (de)
EP (1) EP2292253A3 (de)
CN (1) CN1812808B (de)
AT (1) ATE529126T1 (de)
ES (1) ES2375056T3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
PL2431741T3 (pl) * 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
DK2490708T3 (da) * 2009-10-22 2013-04-15 Biodel Inc Stabiliserede glucagon-opløsninger
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
CN115461044B (zh) * 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
CN115960201B (zh) * 2021-10-09 2023-08-11 合肥天汇生物科技有限公司 一种glp-1类似物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1060192A2 (de) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivate mit einem helixgehalt über 25%, die partiell strukturierte mizellenartige aggregate bilden
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
DE69928006T2 (de) * 1998-12-22 2006-07-13 Eli Lilly And Co., Indianapolis Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
MXPA02007231A (es) * 2000-01-27 2002-12-09 Lilly Co Eli Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs

Also Published As

Publication number Publication date
CN1812808A (zh) 2006-08-02
US20060183682A1 (en) 2006-08-17
EP2292253A3 (de) 2011-12-14
CN1812808B (zh) 2012-07-04
ES2375056T3 (es) 2012-02-24
EP2292253A2 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
ATE529126T1 (de) Stabilisierte pharmazeutische peptid zusammensetzungen
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
MXPA05013048A (es) Composiciones peptodicas farmaceuticas estabilizadas.
PL1633391T3 (pl) Stabilizowane farmaceutycznie kompozycje peptydowe
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
FI20011478A0 (fi) Farmaseuttinen koostumus
WO2006033700A3 (en) Her2 antibody composition
WO2005044234A3 (en) Nanoparticulate compositions having a peptide as a surface stabilizer
IL159022A0 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
DE60225666D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
IS7051A (is) Lyfjasamsetningar
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
DE50305507D1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
WO2007011878A8 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer
DK1790655T3 (da) Biologisk aktive peptider
NO20063293L (no) Farmasoytiske forbindelser
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
ATE409032T1 (de) Orodispersible pharmazeutische zusammensetzung einer antithrombotischen verbindung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties